Clearpoint Neuro Inc
NASDAQ:CLPT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.2502
13.46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Clearpoint Neuro Inc
Clearpoint Neuro Inc
Cash & Cash Equivalents
Clearpoint Neuro Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
Cash & Cash Equivalents
$21.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
28%
|
CAGR 10-Years
28%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Clearpoint Neuro Inc
Glance View
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 80 full-time employees. The company went IPO on 2019-07-03. The Company’s product platforms include SmartFlow Cannula and ClearPoint Navigation System Software. The SmartFlow Cannula is being utilized in approved combination product clinical and preclinical studies by pharmaceutical companies and academic research customers for various research and clinical trials in connection with delivery of therapeutic agents. The ClearPoint Navigation System Software is a software for surgical planning, navigation to target, and device delivery. The Company’s software and MRI-compatible workstation coordinate with the scanner to effectively utilize intraprocedural MR images. This provides real-time navigational instruction for the neurosurgeon to reach the desired anatomical target with a high degree of precision.
See Also
What is Clearpoint Neuro Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
21.6m
USD
Based on the financial report for Sep 30, 2024, Clearpoint Neuro Inc's Cash & Cash Equivalents amounts to 21.6m USD.
What is Clearpoint Neuro Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
28%
Over the last year, the Cash & Cash Equivalents growth was -11%. The average annual Cash & Cash Equivalents growth rates for Clearpoint Neuro Inc have been -28% over the past three years , 28% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet
